Tolazamide

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Tolazamide

Error creating thumbnail: File missing
Clinical data
[[Regulation of therapeutic goods |Template:Engvar data]]	US FDA: Tolazamide
Pregnancy category	AU: C US: C (Risk not ruled out)
Routes of administration	Oral
ATC code	A10BB05 (WHO)
Legal status
Legal status	US: ℞-only
Pharmacokinetic data
Bioavailability	?
Metabolism	?
Elimination half-life	7 hours
Excretion	Renal (85%) and fecal (7%)
Identifiers
IUPAC name 3-azepan-1-yl-1-(4-methylphenyl)sulfonyl-urea
CAS Number	1156-19-0
PubChem CID	5503
DrugBank	APRD01267
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C14H21N3O3S
Molar mass	311.401 g/mol

{{SIB} For patient information, click here

Tolazamide is an oral blood glucose lowering drug used for people with Type 2 diabetes. It is part of the sulfonamide family (ATC A10BB).

External links

• NIH/Medline

Template:WikiDoc Sources